DOCSLIB.ORG

Narcotic Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Narcotic Drugs ElINCB/1992121Supp.10 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 10 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1993 STATISTICS FOR 1991 --------------- -- ---- ESTIMATES UPDATED AS OF 31 OCTOBER 1993 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT NO 10 , A STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1993 STATISTIQUES POUR 1991 EVALUATIONS A JOUR AU 31 OCTOBRE 1993 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 10 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1993 ESTADisTICAS PARA 1991 -- - -----~ . - - -- -------------_._----- PREVISIONES ACTUALlZADAS AL 31 DE OCTUBRE DE 1993 ~f&.~~ ~ ~tJ UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1993 The updating of Table A is carried out by means of 12 monHlly supplements. In order to facilitate the task of the exporting countries, tile 12 supplements now report all tile totals of the estimates and not only the amended data. In this way, eacll supplement cancels and replaces the published table in its entirety in order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the Indexes of countries and territories and of narcotic drugs appearing in the annual publication La mise a Jour du tableau A s'effectLle au moyen de douze supplements mensuels. Afin de facillter la tache des pays exportateurs, les douze supplements conllennent tous les totaux des evaluations et non pas seulement les chlffres qui ont ete modifies De cette maniere, chaque supplement annule et remplace entlerement le tableau publle. En vue d'accelerer la COmmLJrlICa­ tion des supplements aux autorites competentes, les douze supplements seront publies en anglais. La lecture en fran<;;ais et en espagnol de ces douze supplements pourra etre faclllteo par la consultation des index des pays et temtolres el des stupefiants de la publication annuelle La actualizacion del cuadro A se efectua medlante doce suplementos mensuales Para facilitar la tarea de los paises exportadores. en esos doce sLlplomentos figuran todos los totales de las prevlsiones y no solo las cifras que se han modificado De eslo modo, cada suplemento anula y sustituye por completo el cuadro publicado. Con el fin de acelerar la comunicacion de los suplementos alas autoridades nacionales competentes, los doce suplemontos aparecen en ingles. La lectura de estos doce suplementos en espanol y en frances se vera facllitada si se consultan los indices de paises y territorios que figuran en la publicacion anual Ell NCB/1992/2/Supp.1 0 31,10.1993 UNITED NATIONS PUBLICATION ISSN 1013-8250 ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN 1993 TOTAL OF ESTIMATES IN GRAMS ANTIGUA AND BARBUDA AFGHANISTAN ------------------------ ------------------------- COCAINE 24 CODEINE 189 540 CODEINE 600 ETHYLMORPHINE 1 060 FENTANYL 2 FENTANYL 1 MORPHINE 12 METHADONE 50 PETHIDINE 600 MORPHINE 500 OPIUM 8 000 ARGENTINA PETHIDINE 10 000 ------------------------ 3-MONOACETYLMORPHINE 1 ALBANIA ALFENTANIL 400 ------------------------ CANNABIS 10 COCAINE 500 CANNABIS RESIN 30 CODEINE 40 000 COCA LEAF 100 ETHYLMORPHINE 500 COCAINE 2 000 FENTANYL 7 CODEINE 400 000 PETHIDINE 5 000 CONC. OF POPPY STRAW 500 000 DEXTROPROPOXYPHENE 2000 000 ALGERIA DIHYDROCODEINE 80 000 ------------------------ DIPHENOXYLATE 5 000 ALFENTANIL 14 ECGONINE 1 CODEINE 300 000 ECGONINE BENZOYLESTER 1 DEXTROMORAMIDE 650 ECGONINE CYNNAMOYLMETHYLESTER 1 FENTANYL 20 ECGONINE METHYLESTER 1 MORPHINE 300 ETHYLMORPHINE 60 000 PETHIDINE 4 000 FENTANYL 631 PHENOPERIDINE 350 HEROIN 10 PHOLCODINE 200 000 HYDROCODONE 60 000 METHADONE 10 ANDORRA MORPHINE 430 000 ------------------------ OPIUM 10 000 ALFENTANIL 4 OXYCODONE 10 000 COCAINE 10 PETHIDINE 100 000 CODEINE 20 PHOLCODINE 60 010 DEXTROMORAMIDE 10 SUFENTANIL 100 ETHYLMORPHINE 5 THEBAINE 150 001 FENTANYL 3 METHADONE 15 ARMENIA MORPHINE 110 ------------------------ OPIUM 5 PETHIDINE 200 See RUSSIAN FEDERATION PHENOPERID INE 14 TILIDINE 20 ARUBA ANGOLA ------------------------ ------------------------ BEZITRAMIDE 3 CODEINE 7 620 COCAINE 29 DEXTROMORAMIDE 1 CODEINE 35 FENTANYL 15 DEXTROMORAMIDE 1 MORPHINE 30 FENTANYL 1 PETHIDINE 365 HYDROCODONE 1 METHADONE 7 ANGUILLA MORPHINE 171 ------------------------ OPIUM 549 COCAINE 3 OXYCODONE 33 CODEINE 4 PETHIDINE 1 180 DIHYDROCODEINE 14 FENTANYL 2 ASCENSION ISLAND MORPHINE 4 ------------------------ PETHIDINE 68 FENTANYL 3 PAGE 2 TOTAL OF ESTIMATES IN GRAM: MORPHINE 13 AZERBAIJAN PETHIDINE 26 ------------------------ AUSTRALIA See RUSSIAN FEDERATION ------------------------ ALFENTANIL 20 ANILERIDINE 150 000 BAHAMAS CANNABIS 60 ------------------------ COCAINE 16 342 CANNABIS 35 CODEINE 8700 000 COCAINE 60 CONC. OF POPPY STRAW 60970 000 CODEINE 1 800 DEXTROMORAMIDE 6 582 DEXTROPROPOXYPHENE 4 000 DEXTROPROPOXYPHENE 1438 000 FENTANYL 1 DIFENOXIN 10 HYDROCODONE 300 DIHYDROCODEINE 200 000 MORPHINE 300 DIPHENOXYLATE 120 680 OPIUM 20 ETHYLMORPHINE 13 145 OXYCODONE 750 ETORPHINE 5 PETHIDINE 9 000 FENTANYL 650 HEROIN 10 BAHRAIN HYDROCODONE 29 211 ------------------------ HYDROMORPHONE 10 3-METHYLFENTANYL 1 METHADONE 285 904 COCAINE 211 MORPHINE 9908 000 CODEINE 1 015 MORPHINE-3-B-D-GLUCURONIDE 1 ECGONINE BENZOYLESTER 1 MORPHINE-6-B-D-GLUCURONIDE 25 ETORPHINE 2 NORCODEINE 1 FENTANYL 1 NORMETHADONE 1 010 HYDROMORPHONE 1 NORMORPHINE 1 LEVORPHANOL 1 OPIUM 52 142 MORPHINE 547 OXYCODONE 265 752 NORCODEINE 1 OXYMORPHONE 5 000 OXYCODONE 1 PETHIDINE 768 674 OXYMORPHONE 1 PETHIDINE INT.-A 235 000 PETHIDINE 5 000 PHENOPERIDINE 228 PHENOPERIDINE 2 PHOLCODINE 541 618 SUFENTANIL 10 BANGLADESH THEBAINE 1932 000 ------------------------ TILIDINE 50 000 CODEINE 10 650 FENTANYL 10 PETHIDINE 151 380 PHOLCODINE 140 000 AUSTRIA ------------------------ BARBADOS ALFENTANIL 379 ------------------------ ALPHAPRODINE 1 COCAINE 138 COCAINE 2 868 CODEINE 23 000 CODEINE 182 846 DIHYDROCODEINE 356 DEXTROPROPOXYPHENE 224 082 FENTANYL 1 DIHYDROCODEINE 210 347 HYDROCODONE 111 ETHYLMORPHINE 1 578 METHADONE 11 ETORPHINE 10 MORPHINE 466 FENTANYL 252 OXYCODONE 49 HYDROCODONE 100 PETHIDINE 2 455 HYDROMORPHONE 200 METHADONE 44 520 METOPON 1 BELARUS MORPHINE 144 656 ------------------------ MORPHINE-6-GLUCURONIDE 85 NICOCODINE 24 130 See RUSSIAN FEDERATION NICOMORPHINE 13 119 OPIUM 19 187 PETHIDINE 76 719 BELGIUM PIRITRAMIDE 8 470 ------------------------ SUFENTANIL 153 3-MONOACETYLMORPHINE 1 THEBAINE 1 000 6-MONOACETYLMORPHINE 3 ACETYLDIHYDROCODEINE 34 086 ALFENTANIL 40 000 TOTAL OF ESTIMATES IN GRAMS PAGE 3 BEZITRAMIDE 2 729 METHADONE 400 CANNABIS 98 MORPHINE 1 500 COCA LEAF 49 218 OPIUM 100 COCAINE 145 774 OXYCODONE 200 CODEINE 3206 000 OXYMORPHONE 1 CONC. OF POPPY STRAW 2600 000 PETHIDINE 3 000 DEXTROMORAMIDE 47 052 DEXTROPROPOXYPHENE 380 487 BHUTAN DIETHYLTHIAMBUTENE 20 DIFENOXIN 10 CODEINE 3 700 DIHYDROCODEINE 180 440 DEXTROPROPOXYPHENE 450 DIPHENOXYLATE 450 000 MORPHINE 75 DIPIPANONE 60 PETHIDINE 435 ECGONINE BENZOYLESTER 2 ECGONINE METHYLESTER 2 BOLIVIA ETHYLMORPHINE 222 977 ETORPHINE 20 ALFENTANIL 10 ETOXERIDINE 20 COCAINE 25 FENTANYL 17 000 CODEINE 15 170 HEROIN 1 000 DEXTROPROPOXYPHENE 140 000 HYDROCODONE 22 790 DIHYDROCODEINE 2 010 HYDROMORPHONE 1 179 FENTANYL 35 ISOMETHADONE 20 METHADONE 300 LEVOMORAMIDE 910 PETHIDINE 6 000 LEVORPHANOL 20 METHADONE 64 271 BOSNIA AND HERZEGOVINA MORPHINE 3075 000 NICOMORPHINE 20 COCAINE 1 000 NORCODEINE 2 CODEINE 900 000 NORMETHADONE 198 FENTANYL 100 NORMORPHINE 2 METHADONE 1 000 OPIUM 100 000 MORPHINE 1 500 OXYCODONE 3 390 PETHIDINE 3 000 PETHIDINE 44 438 PETHIDINE INT.-B 20 BOTSWANA PHENAZOCINE 20 PHENOPERIDINE 10 CODEINE 432 PHOLCODINE 254 142 DIHYDROCODEINE 1 875 RACEMETHORPHAN 20 DIPIPANONE 25 SUFENTANIL 1 000 FENTANYL 6 THE BACON 42 485 METHADONE 6 THEBAINE 198 486 MORPHINE 1 110 TILIDINE 1604 000 PETHIDINE 6 000 SUFENTANIL 6 BELIZE TILIDINE 125 COCAINE 200 BRAZIL CODEINE 1 500 MORPHINE 50 CODEINE 600 000 PETHIDINE 1 500 DEXTROPROPOXYPHENE 3 000 DIPHENOXYLATE 229 094 BENIN FENTANYL 837 MORPHINE 1882 000 MORPHINE 10 OPIUM 1020 000 OPIUM 1 000 PETHIDINE 500 000 PETHIDINE 1 000 BRITISH VIRGIN ISLANDS BERMUDA CODEINE 600 ALFENTANIL 4 DIHYDROCODEINE 200 COCAINE 200 DIPHENOXYLATE 15 CODEINE 2 000 PETHIDINE 550 DEXTROMORAMIDE 15 DIHYDROCODEINE 1 000 BRUNEI DARUSSALAM ETORPHINE 5 FENTANYL 1 ALFENTANIL 2 CANNABIS 20 COCAINE 2 PAGE 4 TOTAL OF ESTIMATES IN GRAMS CODEINE 100 CANADA ETORPHINE 2 ------------------------ FENTANYL 2 ALFENTANIL 841 HEROIN 2 ALPHAPRODINE 450 METHADONE 2 ANILERIDINE 114 927 MORPHINE 187 COCA LEAF 2 500 OPIUM 60 COCAINE 39 500 PETHIDINE 1 709 CODEINE 16669 000 DEXTROPROPOXYPHENE 1275 000 BULGARIA DIFENOXIN 1 ------------------------ DIHYDROCODEINE 1 ALFENTANIL 50 DIPHENOXYLATE 35 645 COCAINE 37 746 ECGONINE 5 CODEINE 9414 000 ETHYLMORPHINE 100 DEXTROMORAMIDE 70 ETORPHINE 4 DIHYDROCODEINE 200 FENTANYL 1 013 DIPHENOXYLATE 31 050 HEROIN 2 800 DIPIPANONE 1 HYDROCODONE 84 021 ETHYLMORPHINE 332 007 HYDROMORPHONE 91 640 FENTANYL 313 LEVORPHANOL 1 619 HEROIN 2 METHADONE 65 614 METHADONE 150 METHYLCODEINE 2 MORPHINE 507 652 MORPHINE 942 723 OPIUM 1100 000 MORPHINE-6-GLUCURONIDE 1 PETHIDINE 167 003 NORCODEINE 1 PIRITRAMIDE 8 393 NORMETHADONE 30 520 SUFENTANIL 2 NORMORPHINE 1 TILIDINE 65 636 OPIUM 91 157 OXYCODONE 129 608 BURKINA FASO OXYMORPHONE 245 ------------------------ PETHIDINE 938 478 DEXTROMORAMIDE 10 SUFENTANIL 45 FENTANYL 3 THEBAINE 1 PETHIDINE 357 PHENOPERIDINE 2 CAPE VERDE ------------------------ BURUNDI CODEINE 118 -----------~------------
Load more

Recommended publications
  • Screening/Spot Test of Narcotics
    Indian Journal of Forensic and Community Medicine 2020;7(4):160–165 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Forensic and Community Medicine Journal homepage: https://www.ipinnovative.com/journals/IJFCM Review Article Screening/spot test of narcotics A K Jaiswal1,*, Kamna Sharma2, Rohit Kanojia3, Sally Lukose4 1Dept. of Forensic Medicine & Toxicology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 2Galgotias University, Greater Noida, Uttar Pradesh, India 3Dept. of Chemistry, University of Delhi, New Delhi, India 4CTM-IRTE, Faridabad, Haryana, India ARTICLEINFO ABSTRACT Article history: Narcotics are the substances used to treat moderate to severe pain. They could be natural like opiates such Received 25-11-2020 as morphine, codeine etc., synthetic like fentanyl, methadone etc., and semi-synthetic like oxycodone, Accepted 02-12-2020 hydrocodone etc. These drugs act as pain relievers, induces the state of stupor or sleep, and increase Available online 08-01-2021 the physical dependence on them. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including stimulants. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this. The samples must be Keywords: analysed by the forensic toxicologist/chemists/scientist. This article deals with the screening/spot test for Narcotics narcotics. It attempts to simplify the standard procedures in a step-wise manner, which can be of handy Screening reference for the forensic toxicologist. Spot test Drugs © This is an open access article distributed under the terms of the Creative Commons Attribution Opioids etc License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]
  • Federal Register/Vol. 85, No. 36/Monday, February 24, 2020
    10466 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Controlled substance Drug code Schedule Alphamethadol ................................................................................................................................................................. 9605 I Benzethidine .................................................................................................................................................................... 9606 I Betacetylmethadol ........................................................................................................................................................... 9607 I Clonitazene ...................................................................................................................................................................... 9612 I Diampromide ................................................................................................................................................................... 9615 I Diethylthiambutene .......................................................................................................................................................... 9616 I Dimethylthiambutene ....................................................................................................................................................... 9619 I Ketobemidone .................................................................................................................................................................
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Opioid Powders Page: 1 of 9
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 1 of 9 Last Review Date: March 13, 2020 Opioid Powders Description Buprenorphine Powder, Butorphanol Powder, Codeine Powder, Hydrocodone Powder, Hydromorphone Powder, Levorphanol Powder, Meperidine Powder, Methadone Powder, Morphine Powder, Oxycodone Powder, Oxymorphone Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, and oxymorphone powders are opioid drugs that are used for pain control. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death (1-15). Regulatory Status 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 2 of 9 FDA-approved indications: 1.
    [Show full text]
  • Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their
    Products included in the Triplicate Prescription Program* This is a reference list provided for convenience. While all generic medication names appear, only sample brand names are provided and it should not be viewed as an all-inclusive listing of all trade names of drugs included in the Triplicate Prescription Program. BUPRENORPHINE METHADONE BuTrans, Suboxone** Metadol, Methadose - May only be prescribed by physicians Prescription regulations summary chart who hold an approval to prescribe methadone from their BUTALBITAL PREPARATIONS provincial regulatory body*** Summary of federal and provincial laws governing prescription drug ordering, Fiorinal, Fiorinal C ¼ & C ½, Pronal, Ratio-Tecnal, records, prescription requirements, and refills Ratio-Tecnal C ¼ & C ½, Trianal, Trianal C ½ METHYLPHENIDATE Biphentin®, Foquest®, and Concerta® brands are excluded Revised 2019 BUTORPHANOL from TPP prescr ip t i o n p a d req u ir e m e n t s (generic versions Butorphanol NS, PMS-Butorphanol, Torbutrol (Vet), of these products require a triplicate presc ription) Torbugesic (Vet) Apo-Methyphenidate, PHL-Methylphenidate, PMS- Prescription regulations DEXTROPROPOXYPHENE Methylphenidate, PMS-Methylphenidate ER, Ratio- None identified Methylphenidate, Ritalin, Ritalin SR, Sandoz- According to the Standards of Practice for Pharmacists and Pharmacy Technicians: Methylphenidate SR, Teva-Methylphenidate ER-C FENTANYL/SUFENTANIL/ALFENTANIL 6.4 Neither a pharmacist nor a pharmacy technician may dispense a drug or blood product under a Alfentanil Injection,
    [Show full text]
  • A Review of Unique Opioids and Their Conversions
    A Review of Unique Opioids and Their Conversions Jacqueline Cleary, PharmD, BCACP Assistant Professor Albany College of Pharmacy and Health Sciences Adjunct Professor SAGE College of Nursing DISCLOSURES • Kaleo • Remitigate, LLC OBJECTIVES • Compare and contrast unique pharmacotherapy options for the treatment of chronic pain including: methadone, buprenoprhine, tapentadol, and tramadol • Select methadone, buprenorphine, tapentadol, or tramadol based on patient specific factors • Apply appropriate opioid conversion strategies to unique opioids • Understand opioid overdose risk surrounding opioid conversions and the use of unique opioids UNIQUE OPIOIDS METHADONE, BUPRENORPHINE, TRAMADOL, TAPENTADOL METHADONE My favorite drug because….? METHADONE- INDICATIONS • FDA labeled indications – (1) chronic pain (2) detoxification Oral soluble tablets for suspension NOT indicated for chronic pain treatment • Initial inpatient detoxification of opioids by a licensed trained provider with methadone and supportive care is appropriate • Methadone maintenance provider must have special credentialing and training as required by state Outpatient prescription must be for pain ONLY and say “for pain” on RX • Continuation of methadone maintenance from outside provider while patient is inpatient for another condition is appropriate http://cdn.atforum.com/wp-content/uploads/SAMHSA-2015-Guidelines-for-OTPs.pdf MECHANISM OF ACTION • Potent µ-opioid agonist • NMDA receptor antagonist • Norepinephrine reuptake inhibitor • Serotonin reuptake inhibitor ADVERSE EVENTS
    [Show full text]
  • Kappa Opioid Receptor Regulation of Erk1/2 Map Kinase Signaling Cascade
    1 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD A dissertation presented by Khampaseuth Rasakham to The Department of Psychology In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the field of Psychology Northeastern University Boston, Massachusetts August, 2008 2 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD by Khampaseuth Rasakham ABSTRACT OF DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Psychology in the Graduate School of Arts and Sciences of Northeastern University, August, 2008 3 ABSTRACT Activation of the Kappa Opioid Receptor (KOR) modulates dopamine (DA) signaling, and Extracellular Regulated Kinase (ERK) Mitogen-Activated Protein (MAP) kinase activity, thereby potentially regulating the rewarding effects of cocaine. The central hypothesis to be tested is that the time-and drug-dependent KOR-mediated regulation of ERK1/2 MAP kinase activity occurs via distinct molecular mechanisms, which in turn may determine the modulation (suppression or potentiation) by KOR effects on cocaine conditioned place preference (CPP). Three studies were performed to test this hypothesis. Study 1 examined the effects of U50,488 and salvinorin A on cocaine reward. In these studies, mice were treated with equianalgesic doses of agonist from 15 to 360 min prior to daily saline or cocaine place conditioning. At time points corresponding with peak biological activity, both agonists produced saline-conditioned place aversion and suppressed cocaine-CPP, effects blocked by the KOR antagonist nor-BNI. However, when mice were place conditioned with cocaine 90 min after agonist pretreatment, U50,488-pretreated mice demonstrated a 2.5-fold potentiation of cocaine-CPP, whereas salvinorin A-pretreated mice demonstrated normal cocaine-CPP responses.
    [Show full text]
  • Best Bets from the Manchester Royal Infirmary Edited by K Mackway-Jones
    247 BEST EVIDENCE TOPIC REPORTS Emerg Med J: first published as 10.1136/emj.19.3.248 on 1 May 2002. Downloaded from Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary Edited by K Mackway-Jones Clinical scenario Best evidence topic reports (BETs) summarise the evidence A 23 year old woman attends an emergency department hav- pertaining to particular clinical questions. They are not ing taken sixty 500 mg paracetamol tablets. Her four hour systematic reviews, but rather contain the best (highest paracetamol levels are above the treatment line. She does not level) evidence that can be practically obtained by busy want to be treated with intravenous therapy. You wonder practising clinicians. The search strategies used to find the whether oral antidote is as effective. best evidence are reported in detail in order to allow clinicians to update searches whenever necessary. The BETs published below were first reported at the Critical Three part question Appraisal Journal Club at the Manchester Royal Infirmary.1 In [patients who need an antidote for paracetamol overdose] Each BET has been constructed in the four stages that have is [intravenous therapy better than oral therapy] at [prevent- been described elsewhere.2 The BETs shown here together ing liver damage and death]? with those published previously and those currently under construction can be seen at http://www.bestbets.org.3 Six Search strategy BETs are included in this issue of the journal. Medline 1966 to 12/01 using the OVID interface. [exp acetyl-
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Hydromorphone
    Hydromorphone WHAT IS HYDROMORPHONE? sedation, and reduced anxiety. It may also cause Hydromorphone belongs to a class of drugs mental clouding, changes in mood, nervousness, called “opioids,” which includes morphine. It and restlessness. It works centrally (in the has an analgesic potency of two to eight times brain) to reduce pain and suppress cough. greater than that of morphine and has a rapid Hydromorphone use is associated with both onset of action. physiological and psychological dependence. WHAT IS ITS ORIGIN? What is its effect on the body? Hydromorphone is legally manufactured and Hydromorphone may cause: distributed in the United States. However, • Constipation, pupillary constriction, urinary retention, users can obtain hydromorphone from nausea, vomiting, respiratory depression, dizziness, forged prescriptions, “doctor-shopping,” impaired coordination, loss of appetite, rash, slow or theft from pharmacies, and from friends and rapid heartbeat, and changes in blood pressure acquaintances. What are its overdose effects? What are the street names? Acute overdose of hydromorphone can produce: Common street names include: Severe respiratory depression, drowsiness • D, Dillies, Dust, Footballs, Juice, and Smack progressing to stupor or coma, lack of skeletal muscle tone, cold and clammy skin, constricted What does it look like? pupils, and reduction in blood pressure and heart Hydromorphone comes in: rate • Tablets, capsules, oral solutions, and injectable Severe overdose may result in death due to formulations respiratory depression. How is it abused? Which drugs cause similar effects? Users may abuse hydromorphone tablets by Drugs that have similar effects include: ingesting them. Injectable solutions, as well as • Heroin, morphine, hydrocodone, fentanyl, and tablets that have been crushed and dissolved oxycodone in a solution may be injected as a substitute for heroin.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]